Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 16.08 USD -5.13% Market Closed
Market Cap: 1.8B USD

During the last 3 months Novocure Ltd insiders have not bought any shares, and sold 1.1m USD worth of shares. The stock price has dropped by 41% over this period (open performance analysis).

The last transaction was made on Mar 3, 2025 by Paravasthu Mukund (Chief Operating Officer) , who sold 4.6k USD worth of NVCR shares.

Last Transactions:
Paravasthu Mukund
Chief Operating Officer
$-4.6k
Weinberg Uri
Executive Chairman
$-81.3k
Weinberg Uri
Executive Chairman
$-81.3k
Cordova Ashley
Executive Vice President, Global Development
$-186.2k
Paravasthu Mukund
Chief Operating Officer
$-27.5k
Leonard Frank X
Chief Executive Officer
$-204.7k
Puri Michal Nath
Chief Financial Officer
$-23.1k
Leupin Nicolas
Chief Commercial Officer
$-16.5k
Cordova Ashley
Executive Vice President, Global Development
$-186.2k
Leonard Frank X
Chief Executive Officer
$-204.7k
Puri Michal Nath
Chief Financial Officer
$-23.1k
Leupin Nicolas
Chief Commercial Officer
$-16.5k
Paravasthu Mukund
Chief Operating Officer
$-27.5k
Paravasthu Mukund
Chief Operating Officer
$-57.9k
Paravasthu Mukund
Chief Operating Officer
$-734.2
Leonard Frank X
Chief Executive Officer
$-9.5k
Paravasthu Mukund
Chief Operating Officer
$-2.5k
Puri Michal Nath
Chief Financial Officer
$-12.8k
Cordova Ashley
Executive Vice President, Global Development
$-13.9k
Vernon W Anthony
Chief Financial Officer
$-23k
Scannell Timothy J
Chief Development Officer
$-23k
Leung Gabriel
Chief Financial Officer
$-23k
Leonard Frank X
Chief Executive Officer
$-26.9k
Groenhuysen Wilhelmus Cm
Chief Commercial Officer
$-33.8k
Leonard Frank X
Chief Executive Officer
$-33.5k
Groenhuysen Wilhelmus Cm
Chief Commercial Officer
$-37.2k
Shah Pritesh
Chief Operating Officer
$-4.8k
Cordova Ashley
Executive Vice President, Global Development
$-19.3k
Groenhuysen Wilhelmus Cm
Chief Commercial Officer
$-6.4k
Shah Pritesh
Chief Operating Officer
$-6k
Cordova Ashley
Executive Vice President, Global Development
$-34.6k
Leonard Frank X
Chief Executive Officer
$-335.3k
View All Transactions

During the last 3 months Novocure Ltd insiders have not bought any shares, and sold 1.1m USD worth of shares. The stock price has dropped by 41% over this period (open performance analysis).

The last transaction was made on Mar 3, 2025 by Paravasthu Mukund (Chief Operating Officer) , who sold 4.6k USD worth of NVCR shares.

Sold
0-3
months
1.1m USD
6
3-6
months
83.5k USD
3
6-9
months
13.9k USD
1
9-12
months
69.1k USD
3
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Novocure Ltd
Insider Trading Chart

Novocure Ltd
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Novocure Ltd
Last Insider Transactions

Global
Insiders Monitor

Novocure Ltd
Glance View

Market Cap
1.7B USD
Industry
Health Care

Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.

NVCR Intrinsic Value
25.16 USD
Undervaluation 36%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top